Merck gets two Welireg wins
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
ESMO 2025 – no starring role for Exelixis’s Cabometyx follow-on
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Exelixis claims a next-generation colorectal win
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
ASCO 2025 – Exelixis’s son of Cabometyx improves
In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
